MUNDIPHARMA today announced it has entered an exclusive distribution agreement with Medical Developments International Limited (MVP) for the non-opioid pain medication Penthrox (methoxyflurane).
Penthrox is self-administered through a custom-built inhaler under the supervision of a treating healthcare provider, with pain relief starting in six-10 breaths.
The medication is indicated for short-term relief of moderate to severe pain, associated with trauma or interventional medical procedures in conscious patients.
The above article was sent to subscribers in Pharmacy Daily's issue from 04 Jun 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Jun 19
